Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (241-250 of 251) with videos related to

Pageof 26
Sort By:
Annals of the Rheumatic Diseases|January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases|October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature researchJ Avouac, O Kowal-Bielecka, R Landewe, et al.
Annals of the Rheumatic Diseases|October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)D E Furst, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Annals of the Rheumatic Diseases|December 17, 2008
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008D E Furst, E C Keystone, B Kirkham, et al.
Annals of the Rheumatic Diseases|December 10, 2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009D E Furst, E C Keystone, R Fleischmann, et al.
Annals of the Rheumatic Diseases|December 7, 2007
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic goutW J Taylor, H R Schumacher, H S B Baraf, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 26

Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
Annals of the Rheumatic Diseases|January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases|October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature researchJ Avouac, O Kowal-Bielecka, R Landewe, et al.
Annals of the Rheumatic Diseases|October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)D E Furst, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Annals of the Rheumatic Diseases|December 17, 2008
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008D E Furst, E C Keystone, B Kirkham, et al.
Annals of the Rheumatic Diseases|December 10, 2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009D E Furst, E C Keystone, R Fleischmann, et al.
Annals of the Rheumatic Diseases|December 7, 2007
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic goutW J Taylor, H R Schumacher, H S B Baraf, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 26